BOSTON & MOSCOW--(BUSINESS WIRE)--BioNevia LLC and its development partner, NeuroMax Ltd, today announced the completion of enrollment in NM-ARI-231, a Phase 2b randomized, double-blind, placebo-controlled twelve month, chronic efficacy and safety study of BNV-222 (diepalrestat) in adult subjects with diabetic peripheral neuropathy. Four hundred (400) subjects were enrolled in 27 sites in Russia. The ongoing Phase 2b clinical trial evaluates efficacy on motor nerve conduction velocity, clinical
![]()
↧